The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects
Public ClinicalTrials.gov record NCT00146289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group
Study identification
- NCT ID
- NCT00146289
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Interventions
- MICARDIS® (telmisartan) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2005
- Primary completion
- Sep 30, 2005
- Completion
- Not listed
- Last update posted
- Oct 31, 2013
Started 2005
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA School of Medicine- Divison of Endocrinology | Los Angeles | California | — | — |
| University of CA at SanDiego- Department of Endocrinology | San Diego | California | — | — |
| Boehringer Ingelheim Investigational Site | Westlake Village | California | — | — |
| Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| University of Rochester Medical Center | Rochester | New York | — | — |
| Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| Boehringer Ingelheim Investigational Site | Harker Heights | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00146289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00146289 live on ClinicalTrials.gov.